[The indication and the evaluation of IFN treatment of chronic hepatitis C].
The indication and the evaluation of IFN treatment for chronic hepatitis type C has been discussed. Good response to IFN depend on the level of HCV RNA just before the treatment. The patients who has low level of HCV RNA (less than 1 Meq/ml by DNA probe assay) could be able to estimate the response more than 80%. On the contrary, it is less than 10% for the patients with high level of HCV RNA. The evaluation of IFN treatment for chronic hepatitis were divided into 3 groups. Cure was defined as the continuous normalization of serum ALT and disappearance of HCV RNA during 12 month or more after the treatment. Partial response was defined as continuous normalization of ALT level but positive for HCV RNA. The others were defined as non responder. First and second group should be evaluated for the IFN treatment. Final purpose for IFN treatment should be prevent to develop liver cirrhosis or hepatocellular carcinoma.
Yano
M
M
Nagasaki Chuo National Hospital Institute for Clinical Research.
D000410:Alanine Transaminase / Q000097:blood*; D015415:Biomarkers / Q000097:blood*; D002908:Chronic Disease; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D012015:Reference Standards; D016896:Treatment Outcome
D015415:Biomarkers; D012367:RNA, Viral; D007372:Interferons; D000410:Alanine Transaminase